Clinical efficacy of immunotherapy plus target therapy in the treatment of postoperative recurrence of ruptured hepatocellular carcinoma
10.3760/cma.j.cn115610-20210625-00311
- VernacularTitle:免疫联合靶向治疗肝癌破裂出血术后复发的临床疗效
- Author:
Jia YUAN
1
;
Shenxin LU
;
Yiling CAO
;
Miao LI
;
Yuhong GAN
;
Lan ZHANG
Author Information
1. 复旦大学附属中山医院肝肿瘤内科，上海 200032
- Keywords:
Liver neoplasms;
Immunotherapy;
Targeted therapy;
Combination therapy;
Pseudoprogression
- From:
Chinese Journal of Digestive Surgery
2021;20(S2):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Systemic treatment is the first choice for patients with advanced hepatocellular carcinoma. Atezolizumab combined with bevacizumab can bring better survival for patients with advanced hepatocellular carcinoma. The authors introduce the efficacy and safety management of a hepatocellular carcinoma case with postoperative recurrence who received treatment of atezoli-zumab combined with bevacizumab. The patient had a probability of pseudoprogression during treatment, and had a good result of a continuous partial response over 2 years.
